251 related articles for article (PubMed ID: 12632798)
21. No evidence of association between structural polymorphism at the dopamine D3 receptor locus and alcoholism in the Japanese.
Higuchi S; Muramatsu T; Matsushita S; Murayama M
Am J Med Genet; 1996 Jul; 67(4):412-4. PubMed ID: 8837712
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
Scharfetter J
Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
[TBL] [Abstract][Full Text] [Related]
23. The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia.
Hamdani N; Tabeze JP; Ramoz N; Ades J; Hamon M; Sarfati Y; Boni C; Gorwood P
Eur Neuropsychopharmacol; 2008 Jan; 18(1):34-40. PubMed ID: 17669634
[TBL] [Abstract][Full Text] [Related]
24. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L
Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263
[TBL] [Abstract][Full Text] [Related]
25. Association study of dopamine D3 receptor gene and schizophrenia.
Kennedy JL; Billett EA; Macciardi FM; Verga M; Parsons TJ; Meltzer HY; Lieberman J; Buchanan JA
Am J Med Genet; 1995 Dec; 60(6):558-62. PubMed ID: 8825896
[TBL] [Abstract][Full Text] [Related]
26. Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics.
Hamdani N; Bonnière M; Adès J; Hamon M; Boni C; Gorwood P
Neurosci Lett; 2005 Mar; 377(1):69-74. PubMed ID: 15722190
[TBL] [Abstract][Full Text] [Related]
27. No association between schizophrenia and homozygosity at the D3 dopamine receptor gene.
Yang L; Li T; Wiese C; Lannfelt L; Sokoloff P; Xu CT; Zeng Z; Schwartz JC; Liu X; Moises HW
Am J Med Genet; 1993 Jul; 48(2):83-6. PubMed ID: 8103292
[TBL] [Abstract][Full Text] [Related]
28. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
29. The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.
Malhotra AK; Goldman D; Buchanan RW; Rooney W; Clifton A; Kosmidis MH; Breier A; Pickar D
Mol Psychiatry; 1998 Jan; 3(1):72-5. PubMed ID: 9491816
[TBL] [Abstract][Full Text] [Related]
30. Association between schizophrenia and DRD3 or HTR2 receptor gene variants.
Baritaki S; Rizos E; Zafiropoulos A; Soufla G; Katsafouros K; Gourvas V; Spandidos DA
Eur J Hum Genet; 2004 Jul; 12(7):535-41. PubMed ID: 15083167
[TBL] [Abstract][Full Text] [Related]
31. Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system.
Lundstrom K; Turpin MP
Biochem Biophys Res Commun; 1996 Aug; 225(3):1068-72. PubMed ID: 8780735
[TBL] [Abstract][Full Text] [Related]
32. Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting.
Kim B; Choi EY; Kim CY; Song K; Joo YH
Hum Psychopharmacol; 2008 Jan; 23(1):61-7. PubMed ID: 17924589
[TBL] [Abstract][Full Text] [Related]
33. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.
Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448
[TBL] [Abstract][Full Text] [Related]
34. No association between the dopamine D3 receptor Bal I polymorphism and schizophrenia in a family-based study of a Palestinian Arab population.
Kremer I; Rietschel M; Dobrusin M; Mujaheed M; Murad I; Blanaru M; Bannoura I; Müller DJ; Schulze TG; Reshef A; Gathas S; Schwab S; Wildenauer D; Bachner-Melman R; Belmaker RH; Maier W; Ebstein RP
Am J Med Genet; 2000 Dec; 96(6):778-80. PubMed ID: 11121180
[TBL] [Abstract][Full Text] [Related]
35. Dopamine D3 receptor Ser9Gly polymorphism and risperidone response.
Lane HY; Hsu SK; Liu YC; Chang YC; Huang CH; Chang WH
J Clin Psychopharmacol; 2005 Feb; 25(1):6-11. PubMed ID: 15643094
[TBL] [Abstract][Full Text] [Related]
36. Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.
Kaiser R; Tremblay PB; Klufmöller F; Roots I; Brockmöller J
Mol Psychiatry; 2002; 7(7):695-705. PubMed ID: 12192613
[TBL] [Abstract][Full Text] [Related]
37. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine.
Zhao AL; Zhao JP; Zhang YH; Xue ZM; Chen JD; Chen XG
Int J Neurosci; 2005 Nov; 115(11):1539-47. PubMed ID: 16223700
[TBL] [Abstract][Full Text] [Related]
38. Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients.
Vogel M; Pfeifer S; Schaub RT; Grabe HJ; Barnow S; Freyberger HJ; Cascorbi I
Neuropsychobiology; 2004; 50(4):305-10. PubMed ID: 15539862
[TBL] [Abstract][Full Text] [Related]
39. Dopamine D2 receptor gene polymorphisms predict well the response to dopamine antagonists at therapeutic dosages in patients with schizophrenia.
Sakumoto N; Kondo T; Mihara K; Suzuki A; Yasui-Furukori N
Psychiatry Clin Neurosci; 2007 Apr; 61(2):174-80. PubMed ID: 17362435
[TBL] [Abstract][Full Text] [Related]
40. [No association of 141C-ins/del polymorphism in the D2 dopamine receptor gene in schizophrenia].
Rohrmeier T; Putzhammer A; Sartor H; Knapp M; Albus M; Borrmann-Hassenbach M; Lichtermann D; Wildenauer D; Schwab S; Maier W; Klein HE; Eichhammer P
Psychiatr Prax; 2003 May; 30 Suppl 2():S212-5. PubMed ID: 14509080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
